Allergen-specific IgE antibody levels (kUA/L) and CD4 counts in HIV-positive patients with low CD4 counts (#14–21) for whom sequential serum samples were available.

<p>CD4 counts (right y-axes) and allergen-specific IgE levels (left y-axes) measured in serum samples obtained at different points of time (x-axes) are shown. The usual periods of the grass and tree pollen season is indicated in green and brown, respectively.</p

Allergen-specific IgE antibody levels (kUA/L) and CD4 counts in HIV-positive patients with AIDS (#8–11) and in HIV-positive patients with CD4 counts below 200/µl (#12–13).

<p>CD4 counts (right y-axes) and allergen-specific IgE levels (left y-axes) measured in serum samples obtained at different points of time (x-axes) are shown. The usual periods of the grass and tree pollen season is indicated in green and brown, respectively.</p

Demographic, clinical and immunological characterization of ten HIV infected patients with low CD4 counts.

<p>Displayed are age, sex and ranges of CD4 counts for follow-up sera. Allergic symptoms and positive results obtained by skin prick testing and determination of allergen-specific IgE are summarized.</p><p>Abbreviations: F: female; M: male; R: rhinitis; RC: rhinoconjunctivitis; U: urticaria; AB: asthma bronchiale; AP: allergic pharyngitis; SPT: skin prick test; Der p: <i>Dermatophagoides pteronyssinus</i>; n.k.: not known;</p

Frequencies of allergen-specific IgE reactivities in the AD and SE patients as tested by MeDALL allergen chip, Immunoblotting, ImmunoCAP^™ and RAST-based dot-blot assay.

<p>Frequencies of allergen-specific IgE reactivities in the AD and SE patients as tested by MeDALL allergen chip, Immunoblotting, ImmunoCAP^™ and RAST-based dot-blot assay.</p

Pie charts showing the contribution of (A), allergen sources and (B), individual allergen components to IgE sensitization.

<p>Each chart represents 100% of IgE reactivities detected in plasma from all AD patients of the respective group, severe AD (left chart) and moderate AD (right chart), in (<b>A)</b> to six allergen sources using the MeDALL allergen-chip (ISU ≥ 0.3) and to extracts of <i>M</i>. <i>sympodialis</i>, <i>S</i>. <i>aureus</i> and the human cell line A431 using immunoblotting, and in (<b>B)</b> to 25 allergen molecules using the MeDALL allergen-chip (ISU ≥ 0.3). The sizes of the segments represent the proportion of the respective in (<b>A)</b>, allergen source and in (<b>B)</b>, allergen molecule among all recognized. Allergen sources/molecules start a 12 o’clock of the pie chart and continue clock-wise as listed with the color code.</p

Summary of allergen-specific IgE reactivities in the AD patients.

<p>Summary of allergen-specific IgE reactivities in the AD patients.</p

Demographic and clinical characterization of AD patients and controls.

<p>Demographic and clinical characterization of AD patients and controls.</p

Genetic loci associated with the risk of having high IgE response to both Ascaris and common allergens.

<p>A) Effects of <i>CHI3L1</i> rs4950928 on the risk of high IgE response to ABA-1 (filled circle) and to the pollen allergen Bet v 1 (white triangle). The association with ABA-1 was detected in the CGA cohort and the association with Bet v 1 in the Swedish Eczema Cohort. <b>B)</b> Effect of <i>ABDH13</i> rs3783118 on the risk of high IgE response (≥75^th percentile) to the extracts of <i>Ascaris</i> and HDM in the CGA dataset. Risk of IgE response to the <i>Ascaris</i> extract (filled square); Risk of IgE response to the <i>D</i>. <i>pteronyssinus</i> extract (filled triangle). OR: Odds ratio; CI: confidence interval.</p

Burden of 70 single nucleotide variants with differential enrichment between high (≥75^th percentile) and low (≤25^th percentile) IgE responders to Ascaris and ABA-1.

<p>Each column corresponds to the pattern of one individual. The color scale indicates the reference genotype (grey) or the presence of single nucleotide variants in heterozygous (blue) or homozygous (red).</p

Haplotype association between genetic variants in <i>CHIA</i> and IgE response to ABA-1 in the CGA cohort (n = 988)

<p>Haplotype association between genetic variants in <i>CHIA</i> and IgE response to ABA-1 in the CGA cohort (n = 988)</p